Enhanced induction of HIV-specific cytotoxic t lymphocytes by dendritic cell-targeted delivery of SOCS-1 siRNA

Molecular Therapy

Volumn 18, Issue 11, 2010, Pages 2028-2037

  Subramanya, Sandesh ^a,b   Armant, Myriam ^a   Salkowitz, Janelle R ^c   Nyakeriga, Alice M ^c   Haridas, Viraga ^a   Hasan, Maroof ^b   Bansal, Anju ^d   Goepfert, Paul A ^d   Wynn, Katherine K ^e   Ladell, Kristin ^e   Price, David A ^e   N, Manjunath ^a,b   Kan Mitchell, June ^c   Shankar, Premlata ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Paul L Foster School of Medicine   (United States)

^c UNIVERSITY OF TEXAS AT EL PASO   (United States)

^d UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^e CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAG PROTEIN; HLA A ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MELAN A; PEPTIDE; PROTEIN DC3 9DR; SMALL INTERFERING RNA; SUPPRESSOR OF CYTOKINE SIGNALING 1; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW CELL; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RESPONSE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED LYMPHOCYTE REACTION; T LYMPHOCYTE ACTIVATION; TARGET CELL; VACCINE PRODUCTION;

HUMAN IMMUNODEFICIENCY VIRUS; MUS;

EID: 78049483587     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.148     Document Type: Article

References (48)

1. Buchbinder, SP, Mehrotra, DV, Duerr, A, Fitzgerald, DW, Mogg, R, Li, D et al.; Step Study Protocol Team. (2008). Effcacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1881-1893.
2. Liu, J, O'Brien, KL, Lynch, DM, Simmons, NL, La Porte, A, Riggs, AM et al. (2009). Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457: 87-91.
3. Mellman, I, Turley, SJ and Steinman, RM (1998). Antigen processing for amateurs and professionals. Trends Cell Biol 8: 231-237.
4. Steinman, RM (2007). Dendritic cells: understanding immunogenicity. Eur J Immunol 37 Suppl 1: S53-S60.
5. Nicholson, SE and Hilton, DJ (1998). The SOCS proteins: a new family of negative regulators of signal transduction. J Leukoc Biol 63: 665-668.
6. Alexander, WS, Starr, R, Metcalf, D, Nicholson, SE, Farley, A, Elefanty, AG et al. (1999). Suppressors of cytokine signaling (SOCS): negative regulators of signal transduction. J Leukoc Biol 66: 588-592.
7. Shen, L, Evel-Kabler, K, Strube, R and Chen, SY (2004). Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specifc anti-tumor immunity. Nat Biotechnol 22: 1546-1553.
8. Zhou, H, Zhang, D, Wang, Y, Dai, M, Zhang, L, Liu, W et al. (2006). Induction of CML28-specifc cytotoxic T cell responses using co-transfected dendritic cells with CML28 DNA vaccine and SOCS1 small interfering RNA expression vector. Biochem Biophys Res Commun 347: 200-207.
9. Cooney, RN (2002). Suppressors of cytokine signaling (SOCS): inhibitors of the JAK/ STAT pathway. Shock 17: 83-90.
10. Zhang, JG, Metcalf, D, Rakar, S, Asimakis, M, Greenhalgh, CJ, Willson, TA et al. (2001). The SOCS box of suppressor of cytokine signaling-1 is important for inhibition of cytokine action in vivo. Proc Natl Acad Sci USA 98: 13261-13265.
11. Hanada, T, Yoshida, H, Kato, S, Tanaka, K, Masutani, K, Tsukada, J et al. (2003). Suppressor of cytokine signaling-1 is essential for suppressing dendritic cell activation and systemic autoimmunity. Immunity 19: 437-450.
12. Jackson, SH, Yu, CR, Mahdi, RM, Ebong, S and Egwuagu, CE (2004). Dendritic cell maturation requires STAT1 and is under feedback regulation by suppressors of cytokine signaling. J Immunol 172: 2307-2315.
13. + dendritic cell subset. Int Immunol 17: 1167-1178.
14. Bartz, H, Avalos, NM, Baetz, A, Heeg, K and Dalpke, AH (2006). Involvement of suppressors of cytokine signaling in toll-like receptor-mediated block of dendritic cell differentiation. Blood 108: 4102-4108.
15. Subramanya, S, Kim, SS, Abraham, S, Yao, J, Kumar, M, Kumar, P et al. (2010). Targeted delivery of small interfering RNA to human dendritic cells to suppress dengue virus infection and associated proinfammatory cytokine production. J Virol 84: 2490-2501.
16. Marques, JT and Williams, BR (2005). Activation of the mammalian immune system by siRNAs. Nat Biotechnol 23: 1399-1405.
17. Song, E, Zhu, P, Lee, SK, Chowdhury, D, Kussman, S, Dykxhoorn, DM et al. (2005). Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 23: 709-717.
18. Marincola, FM, Rivoltini, L, Salgaller, ML, Player, M and Rosenberg, SA (1996). Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells. J Immunother Emphasis Tumor Immunol 19: 266-277.
19. Wieckowski, S, Baumgaertner, P, Corthesy, P, Voelter, V, Romero, P, Speiser, DE et al. (2009). Fine structural variations of αβTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients. J Immunol 183: 5397-5406.
20. Serana, F, Sottini, A, Caimi, L, Palermo, B, Natali, PG, Nisticò, P et al. (2009). Identifcation of a public CDR3 motif and a biased utilization of T-cell receptor Vβ and Jβ chains in HLA-A2/Melan-A-specifc T-cell clonotypes of melanoma patients. J Transl Med 7: 21.
21. Zippelius, A, Pittet, MJ, Batard, P, Rufer, N, de Smedt, M, Guillaume, P et al. (2002). Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J Exp Med 195: 485-494.
22. Zhang, D, Shankar, P, Xu, Z, Harnisch, B, Chen, G, Lange, C et al. (2003). Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic. Blood 101: 226-235.
23. +) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 192: 63-75.
24. + HIV-specifc T cells during progression to AIDS. Blood 99: 2505-2511.
25. + T cells. J Exp Med 200: 701-712.
26. Song, XT, Evel-Kabler, K, Rollins, L, Aldrich, M, Gao, F, Huang, XF et al. (2006). An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells. PLoS Med 3: e11.
27. Evel-Kabler, K, Song, XT, Aldrich, M, Huang, XF and Chen, SY (2006). SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. J Clin Invest 116: 90-100.
28. Manjunath, N, Wu, H, Subramanya, S and Shankar, P (2009). Lentiviral delivery of short hairpin RNAs. Adv Drug Deliv Rev 61: 732-745.
29. Johnson, TS, Mahnke, K, Storn, V, Schönfeld, K, Ring, S, Nettelbeck, DM et al. (2008). Inhibition of melanoma growth by targeting of antigen to dendritic cells via an anti-DEC-205 single-chain fragment variable molecule. Clin Cancer Res 14: 8169-8177.
30. Tacken, PJ, Torensma, R and Figdor, CG (2006). Targeting antigens to dendritic cells in vivo. Immunobiology 211: 599-608.
31. Altin, JG, van Broekhoven, CL and Parish, CR (2004). Targeting dendritic cells with antigen-containing liposomes: antitumour immunity. Expert Opin Biol Ther 4: 1735-1747.
32. + T cells in a spectrum of human MHC I haplotypes. Proc Natl Acad Sci USA 104: 1289-1294.
33. Kumar, P, Wu, H, McBride, JL, Jung, KE, Kim, MH, Davidson, BL et al. (2007). Transvascular delivery of small interfering RNA to the central nervous system. Nature 448: 39-43.
34. Kumar, P, Ban, HS, Kim, SS, Wu, H, Pearson, T, Greiner, DL et al. (2008). T cell-specifc siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 134: 577-586.
35. Weissman, D, Ni, H, Scales, D, Dude, A, Capodici, J, McGibney, K et al. (2000). HIV gag mRNA transfection of dendritic cells (DC) delivers encoded antigen to MHC class I and II molecules, causes DC maturation, and induces a potent human in vitro primary immune response. J Immunol 165: 4710-4717.
36. Gruber, A, Kan-Mitchell, J, Kuhen, KL, Mukai, T and Wong-Staal, F (2000). Dendritic cells transduced by multiply deleted HIV-1 vectors exhibit normal phenotypes and functions and elicit an HIV-specifc cytotoxic T-lymphocyte response in vitro. Blood 96: 1327-1333.
37. + T cells. Blood 107: 4781-4789.
38. + T cells is required for HIV-infected cell elimination associated with immune control. Immunity 29: 1009-1021.
39. Yoo, J, Chen, H, Kraus, T, Hirsch, D, Polyak, S, George, I et al. (1996). Altered cytokine production and accessory cell function after HIV-1 infection. J Immunol 157: 1313-1320.
40. Grassi, F, Hosmalin, A, McIlroy, D, Calvez, V, Debré, P and Autran, B (1999). Depletion in blood CD11c-positive dendritic cells from HIV-infected patients. AIDS 13: 759-766.
41. Marine, JC, Topham, DJ, McKay, C, Wang, D, Parganas, E, Stravopodis, D et al. (1999). SOCS1 defciency causes a lymphocyte-dependent perinatal lethality. Cell 98: 609-616.
42. Starr, R, Metcalf, D, Elefanty, AG, Brysha, M, Willson, TA, Nicola, NA et al. (1998). Liver degeneration and lymphoid defciencies in mice lacking suppressor of cytokine signaling-1. Proc Natl Acad Sci USA 95: 14395-14399.
43. Henson, SM, Macaulay, R, Kiani-Alikhan, S and Akbar, AN (2008). The use of the inhibitory receptors for modulating the immune responses. Curr Pharm Des 14: 2643-2650.
44. Day, CL, Kaufmann, DE, Kiepiela, P, Brown, JA, Moodley, ES, Reddy, S et al. (2006). PD-1 expression on HIV-specifc T cells is associated with T-cell exhaustion and disease progression. Nature 443: 350-354.
45. + T cell survival in HIV infection. J Exp Med 203: 2281-2292.
46. + T cell repertoire specifc for the subdominant HLA-A2-restricted HIV-1 Gag p2419-27 epitope. J Immunol 178: 7756-7766.
47. + T cell populations specifc for persistent DNA viruses. J Exp Med 202: 1349-1361.
48. Lefranc, M P, Pommié, C, Ruiz, M, Giudicelli, V, Foulquier, E, Truong, L et al. (2003). IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains. Dev Comp Immunol 27: 55-77.